Springer Handbook of Inorganic Photochemistry pp 1015–1033It costs $30 US to download this chapter. The Google search results include this tantalyzing mention of TLD1433:
"Arguably the most successful Ru2+ PDT photosensitizer to date is TLD-1433 (Fig. 34.2a), developed by the group of McFarland. The drug has displayed PI ..." Photomedicine with Inorganic Complexes: A Bright Future Michael S. Meijer, Rose Maria Carlos, Mauricio S. Baptista & Sylvestre Bonnet
Chapter
First Online: 26 June 2022
Part of the Springer Handbooks book series (SHB)
Abstract
Photo-induced reactions have the potential to revolutionize the fields of photomedicine and intelligent drug delivery by providing means of specifically inducing a chemical transformation in biological environments. The molecule that absorbs light and engages in photo-induced reactions is called the photosensitizer, and is the key component in this process. It transforms photon energy into a variety of reactions, such as photosensitized oxidations in photodynamic therapy (PDT) and ligand exchange in photoactivated chemotherapy (PACT). Ruthenium complexes, in particular, offer the possibility to maximize and fine-tune each of these reactions by changing the electronic properties, hydrophobicity, and steric hindrance of the ligands, thus affecting the energy and reactivity of the excited states. The field has advanced immensely in the last decade and we aim here to report on major achievements of ruthenium compounds for phototherapy. We will also discuss the mechanism of light-induced toxicity, the potential of upconverting systems for the activation of this type of drugs, as well as initial steps towards commercial applications of ruthenium complexes as PDT agents.